FY2025 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Equities research analysts at Zacks Research cut their FY2025 earnings estimates for shares of Bruker in a note issued to investors on Monday, February 10th. Zacks Research analyst R. Department now expects that the medical research company will earn $2.73 per share for the year, down from their previous forecast of $2.76. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.92 EPS, Q4 2026 earnings at $0.84 EPS and FY2026 earnings at $3.32 EPS.

BRKR has been the subject of several other research reports. UBS Group started coverage on shares of Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price for the company. Barclays reduced their target price on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research note on Monday. Wells Fargo & Company reduced their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price for the company in a research note on Thursday, December 5th. Finally, Bank of America raised their price objective on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $74.09.

Bruker Stock Performance

NASDAQ BRKR opened at $51.65 on Wednesday. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The firm has a market cap of $7.83 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 3.81 and a beta of 1.16. The company has a fifty day moving average price of $57.88 and a 200-day moving average price of $60.77.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien bought 100,000 shares of Bruker stock in a transaction dated Monday, November 18th. The stock was purchased at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the purchase, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

Large investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC boosted its position in shares of Bruker by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 177 shares during the period. Arizona State Retirement System boosted its position in shares of Bruker by 0.7% in the fourth quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company’s stock valued at $1,801,000 after acquiring an additional 222 shares during the period. CIBC Asset Management Inc boosted its position in shares of Bruker by 5.6% in the fourth quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company’s stock valued at $248,000 after acquiring an additional 223 shares during the period. UMB Bank n.a. boosted its position in shares of Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 248 shares during the period. Finally, Blue Trust Inc. boosted its position in shares of Bruker by 13.5% in the fourth quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company’s stock valued at $127,000 after acquiring an additional 257 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.